On June 20, 2018, Idorsia announced that the first patient had been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.


Find information on this page to support you with covering the news.

Media release

Investor webcast

An investor conference call and webcast will be held to discuss the Phase 3 program. The call will start with presentations by senior management, followed by a Q&A session (live access to the speakers).

 

Date:         Wednesday June 20, 2018

Time:        14:00 CEST | 13:00 BST | 08:00 EDT

 

Webcast participants should visit Idorsia’s website www.idorsia.com 10-15 minutes before the webcast is due to start.

Conference call participants should start calling the number below 10-15 minutes before the conference is due to start.

 

Dial-in:      CH: +41 (0)44 580 65 22 | UK: +44 203 009 2470 | US: +1 877 423 0830

PIN:           67188992#

Are you looking for information on resistant hypertension?

Are you looking for information on resistant hypertension?